RCKT
What one share of Rocket Pharmaceuticals holds
Pharmaceutical Preparations
We are a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need.
Rocket Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.15 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.51 |
| Cash and investments | $2.05 |
| Book value | $3.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$1.11 | $0.05 | −$0.85 | — | $1.24 |
| 2017 | $0.00 | −$2.88 | $0.11 | −$2.46 | — | $2.28 |
| 2018 | $0.00 | −$1.89 | $0.04 | −$1.40 | — | $4.30 |
| 2019 | $0.00 | −$1.58 | $0.47 | −$1.79 | — | $5.61 |
| 2020 | $0.00 | −$2.52 | $0.37 | −$1.72 | — | $8.25 |
| 2021 | $0.00 | −$2.67 | $0.12 | −$2.04 | — | $7.05 |
| 2022 | $0.00 | −$3.26 | $0.12 | −$2.74 | — | $6.19 |
| 2023 | $0.00 | −$2.92 | $0.20 | −$2.52 | — | $5.46 |
| 2024 | $0.00 | −$2.73 | $0.06 | −$2.27 | — | $4.35 |
| 2025 | $0.00 | −$2.01 | $0.00 | −$1.71 | — | $2.56 |